Literature DB >> 15949772

Emerging therapeutic approaches for osteogenesis imperfecta.

Sophia Millington-Ward1, Helena P McMahon, G Jane Farrar.   

Abstract

Osteogenesis imperfecta (OI) is an incurable genetic brittle-bone disease. Although drug therapy, surgery and physiotherapy represent current treatments for OI, the search is ongoing for effective and innovative new therapies targeting the underlying causes of the disease. In this regard, recent advances in the fields of gene and stem-cell therapies have been considerable. In spite of the many challenges that remain, potential new therapies for OI, which have been tested in cell culture systems, animal models and patients, offer hope for the future development of successful therapies. Recent progress in the field is reviewed here.

Entities:  

Mesh:

Year:  2005        PMID: 15949772     DOI: 10.1016/j.molmed.2005.04.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  12 in total

Review 1.  Treatment of children with osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

Review 2.  Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.

Authors:  John F Bateman; Raymond P Boot-Handford; Shireen R Lamandé
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

3.  Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection.

Authors:  Yoshihito Ishida; Akitsugu Yamamoto; Akira Kitamura; Shireen R Lamandé; Tamotsu Yoshimori; John F Bateman; Hiroshi Kubota; Kazuhiro Nagata
Journal:  Mol Biol Cell       Date:  2009-04-08       Impact factor: 4.138

Review 4.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

Review 5.  Osteogenesis imperfecta: diagnosis and treatment.

Authors:  A Biggin; C F Munns
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 6.  Tooth dentin defects reflect genetic disorders affecting bone mineralization.

Authors:  S Opsahl Vital; C Gaucher; C Bardet; P S Rowe; A George; A Linglart; C Chaussain
Journal:  Bone       Date:  2012-01-26       Impact factor: 4.398

7.  Potential implications of cell therapy for osteogenesis imperfecta.

Authors:  Christopher Niyibizi; Feng Li
Journal:  Int J Clin Rheumtol       Date:  2009-02-01

8.  In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.

Authors:  Cristina Panaroni; Roberta Gioia; Anna Lupi; Roberta Besio; Steven A Goldstein; Jaclynn Kreider; Sergey Leikin; Juan Carlos Vera; Edward L Mertz; Egon Perilli; Fabio Baruffaldi; Isabella Villa; Aurora Farina; Marco Casasco; Giuseppe Cetta; Antonio Rossi; Annalisa Frattini; Joan C Marini; Paolo Vezzoni; Antonella Forlino
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

9.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

10.  Prospects and limitations of improving skeletal growth in a mouse model of spondyloepiphyseal dysplasia caused by R992C (p.R1192C) substitution in collagen II.

Authors:  Machiko Arita; Jolanta Fertala; Cheryl Hou; James Kostas; Andrzej Steplewski; Andrzej Fertala
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.